Dynavax Technologies Overview
Company Headquarters: California, US
Founded: 1996
Workforce: ~351
Company Working: Dynavax Technologies is a commercial-stage biopharmaceutical business with extensive experience and skill in vaccine development and commercialization. The company has established several clinical and preclinical collaborations with vaccine developers to evaluate vaccine product candidates against influenza, other infectious diseases, and particularly COVID-19 across a variety of vaccine platforms. It is focused on building an innovative pipeline of investigational vaccine product candidates, leveraging its proven, proprietary vaccine adjuvant technology
Strategy
Establishing collaborative agreements to help fund the development and commercialization of its product candidates and research programs is a significant component of Dynavax Technologies’ business strategy for items in development. The principal goals of the company are to make HEPLISAV-B the standard of treatment in the US for adult hepatitis B immunization and to establish CpG 1018 as a premier vaccine adjuvant



